@article{0c6acb83ad0d497fadb24979b985b048,
title = "Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211",
abstract = "The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log10 copies/μL at day 14 and -1.91 versus -0.57 log10 copies/μL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.",
author = "Zhaohui Su and Gulick, {Roy M.} and Amy Krambrink and Eoin Coakley and Hughes, {Michael D.} and Dong Han and Charles Flexner and Wilkin, {Timothy J.} and Skolnik, {Paul R.} and Greaves, {Wayne L.} and Kuritzkes, {Daniel R.} and Reeves, {Jacqueline D.}",
note = "Funding Information: Financial support: AIDS Clinical Trials Group (ACTG)/National Institute of Allergy and Infectious Diseases/National Institutes of Health (grant AI-68636) and Statistical Data Management Center (grant AI68634), Cornell Clinical Trials Unit (grant AI-69419), Cornell Clinical and Translational Science Center (grant RR024996), K24 AI51966 (to R.M.G.), and K23 AI55038 (to T.J.W.), Johns Hopkins AIDS Clinical Trial Unit (ACTU; grant AI27668), Penn AIDS Clinical Trials Unit (grant U01-AI32783), Penn Center for AIDS Research (grant P30-AI45008), and Harvard–Boston Medical Center ACTU (grant AI27659). Tropism testing performed using the enhanced Trofile assay was supported by Monogram Biosciences. Funding Information: Potential conflicts of interest: J.D.R. and E.C. are employed by Monogram Biosciences. M.D.H. is a paid member of the data and safety monitoring board of Boehringer Ingelheim, Tibotec Pharmaceuticals, and Virionyx. C.F. has served on a scientific advisory board for Schering-Plough. W.L.G. is employed by Schering-Plough Research Institute. D.R.K. is a consultant to Schering-Plough and Monogram Biosciences and has received research funding from Schering-Plough. R.M.G. receives research grant support from Pfizer and Schering-Plough and has served as an ad hoc consultant for Monogram Biosciences, Pathway, Pfizer and Schering-Plough. T.J.W. is an ad hoc consultant for Pfizer. All other authors: no conflicts.",
year = "2009",
month = nov,
doi = "10.1086/648090",
language = "English (US)",
volume = "200",
pages = "1724--1728",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "11",
}